World Pharmacogenomics Journals
Pharmacogenomics (PGx) aims to determine the influence of genetic and genomic variations on drug responses, in other words, drug efficacy and toxicity, and it represents an essential step toward personalization of medicine .Despite the initial enthusiasm with the advent of PGx, its incorporation into the clinic has been frustratingly slow, and so far it has not met the expectations of the academic community, physicians and healthcare professionals. Many barriers that hinder this process have been identified, such as the lack of reimbursement of costs of PGx testing, and the lack of knowledge of healthcare professionals in the interpretation of PGx tests and the consequent treatment decisions. Several studies have shown that medical professionals agree on the importance of PGx in clinical practice, but that they are reluctant to use PGx due to inadequate knowledge of the interpretation of PGx tests.
Pharmacogenomics is one of the doors to enter the complex building of personalized medicine. The introduction of
pharmacogenomics in
drug development and therefore the inclusion of pharmacogenomic
information on drug labels, with specific warnings for the population in danger.
Pharmacogenomics results for ≈80% variability in drug efficacy and safety. In
cardiovascular disorders, the most concern is response to
drugs including warfarin, clopidogrel, beta blockers, and statins. In patients with CYP2C19, who take clopidogrel,
cardiovascular risk is elevated, leading to medication package insert updates by regulators.
High Impact List of Articles
Relevant Topics in Medical